These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 19674285)

  • 61. Interferon therapy of acute hepatitis C in dialysis patients: meta-analysis.
    Fabrizi F; Dixit V; Messa P; Martin P
    J Viral Hepat; 2012 Nov; 19(11):784-91. PubMed ID: 23043385
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
    Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
    J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Acute hepatitis C virus infection in incarcerated injection drug users.
    McGovern BH; Wurcel A; Kim AY; Schulze zur Wiesch J; Bica I; Zaman MT; Timm J; Walker BD; Lauer GM
    Clin Infect Dis; 2006 Jun; 42(12):1663-70. PubMed ID: 16705568
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
    Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Peginterferon-alfa mono-therapy in the treatment of acute hepatitis C in HIV-infection.
    Boesecke C; van Assen S; Stellbrink HJ; Baumgarten A; Ingiliz P; Strassburg CP; Schwarze-Zander C; Wasmuth JC; Hoepelman AI; Rockstroh JK; Arends JE
    J Viral Hepat; 2014 Nov; 21(11):780-5. PubMed ID: 25040149
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Lack of full CD8 functional restoration after antiviral treatment for acute and chronic hepatitis C virus infection.
    Missale G; Pilli M; Zerbini A; Penna A; Ravanetti L; Barili V; Orlandini A; Molinari A; Fasano M; Santantonio T; Ferrari C
    Gut; 2012 Jul; 61(7):1076-84. PubMed ID: 22337949
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Management of acute hepatitis C.
    Maheshwari A; Thuluvath PJ
    Clin Liver Dis; 2010 Feb; 14(1):169-76; x. PubMed ID: 20123448
    [TBL] [Abstract][Full Text] [Related]  

  • 68. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response.
    Mangia A; Thompson AJ; Santoro R; Piazzolla V; Tillmann HL; Patel K; Shianna KV; Mottola L; Petruzzellis D; Bacca D; Carretta V; Minerva N; Goldstein DB; McHutchison JG
    Gastroenterology; 2010 Sep; 139(3):821-7, 827.e1. PubMed ID: 20621700
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma.
    He S; Lockart I; Alavi M; Danta M; Hajarizadeh B; Dore GJ
    Aliment Pharmacol Ther; 2020 Jan; 51(1):34-52. PubMed ID: 31808566
    [TBL] [Abstract][Full Text] [Related]  

  • 70. No evidence of occult hepatitis C or E virus infections in liver-transplant patients with sustained virological response after therapy with direct acting agents.
    Del Bello A; Abravanel F; Alric L; Lavayssiere L; Lhomme S; Bellière J; Izopet J; Kamar N
    Transpl Infect Dis; 2019 Aug; 21(4):e13093. PubMed ID: 30972874
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Acute hepatitis C: a systematic review.
    Kamal SM
    Am J Gastroenterol; 2008 May; 103(5):1283-97; quiz 1298. PubMed ID: 18477352
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Evaluation of the Performance of Algorithms That Use Serial Hepatitis C RNA Tests to Predict Treatment Initiation and Sustained Virological Response Among Patients Infected With Hepatitis C Virus.
    Osinubi A; Harris AM; Vellozzi C; Lom J; Miller L; Millman AJ
    Am J Epidemiol; 2019 Mar; 188(3):555-561. PubMed ID: 30535062
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Course of hepatitis C virus (HCV) RNA and HCV core antigen testing are predictors for reaching sustained virologic response in liver transplant recipients undergoing sofosbuvir treatment in a real-life setting.
    Pischke S; Polywka S; Proske VM; Lang M; Jordan S; Nashan B; Lohse AW; Sterneck M
    Transpl Infect Dis; 2016 Feb; 18(1):141-5. PubMed ID: 26485543
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The Achievement of a Sustained Virological Response Either Before or After Hepatectomy Improves the Prognosis of Patients with Primary Hepatitis C Virus-Related Hepatocellular Carcinoma.
    Okamura Y; Sugiura T; Ito T; Yamamoto Y; Ashida R; Ohgi K; Uesaka K
    Ann Surg Oncol; 2019 Dec; 26(13):4566-4575. PubMed ID: 31602577
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A systematic review and meta-analysis of community and primary-care-based hepatitis C testing and treatment services that employ direct acting antiviral drug treatments.
    Radley A; Robinson E; Aspinall EJ; Angus K; Tan L; Dillon JF
    BMC Health Serv Res; 2019 Oct; 19(1):765. PubMed ID: 31660966
    [TBL] [Abstract][Full Text] [Related]  

  • 76. HIV and hepatitis C co-infection: acute HCV therapy.
    Boesecke C; Vogel M
    Curr Opin HIV AIDS; 2011 Nov; 6(6):459-64. PubMed ID: 22001891
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C.
    Sagnelli E; Pisaturo M; Stanzione M; Messina V; Alessio L; Sagnelli C; Starace M; Pasquale G; Coppola N
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1174-1180.e11. PubMed ID: 23591280
    [TBL] [Abstract][Full Text] [Related]  

  • 78. IL28B gene polymorphism is correlated with changes in low-density lipoprotein cholesterol levels after clearance of hepatitis C virus using direct-acting antiviral treatment.
    Morihara D; Ko YL; Shibata K; Yamauchi R; Fukuda H; Tsuchiya N; Fukunaga A; Kunimoto H; Iwashita H; Takata K; Tanaka T; Sakurai K; Inomata S; Yokoyama K; Nishizawa S; Takeyama Y; Irie M; Shakado S; Sohda T; Sakisaka S
    J Gastroenterol Hepatol; 2019 Nov; 34(11):2019-2027. PubMed ID: 31144350
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Acute hepatitis C: a 24-week course of pegylated interferon α-2b versus a 12-week course of pegylated interferon α-2b alone or with ribavirin.
    Santantonio T; Fasano M; Sagnelli E; Tundo P; Babudieri S; Fabris P; Toti M; Di Perri G; Marino N; Pizzigallo E; Angarano G;
    Hepatology; 2014 Jun; 59(6):2101-9. PubMed ID: 24442928
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Programmable RNA detection with CRISPR-Cas12a.
    Rananaware SR; Vesco EK; Shoemaker GM; Anekar SS; Sandoval LSW; Meister KS; Macaluso NC; Nguyen LT; Jain PK
    Nat Commun; 2023 Sep; 14(1):5409. PubMed ID: 37669948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.